109 -4 (66) 2024 - Artykova M.A., Mamasoliev Sh.M. - FEATURES OF THE PSYCHOEMOTIONAL SPHERE IN PATIENTS WITH METABOLIC SYNDROME

FEATURES OF THE PSYCHOEMOTIONAL SPHERE IN PATIENTS WITH METABOLIC SYNDROME

Artykova M.A. Bukhara State Medical Institute named after Abu Ali ibn Sina

Mamasoliev Sh.M. Andijan State Medical Institute of Uzbekistan

Resume

Purpose of the study. To evaluate changes in the psychoemotional sphere in metabolic syndrome. A comprehensive examination of 241 patients selected from among those undergoing outpatient and inpatient treatment at the Andrei State Medical Institute clinic was carried out. Their average age was 43.7 ± 10.8 (from 29 to 72 years). The developed algorithm, which was used to examine patients with MS, included: questioning using a specially designed questionnaire, collecting complaints, life history and illness, measuring arterial hypertension, detecting obesity, impaired glucose tolerance; objective examination: general examination, anthropometry, interpretation of laboratory examination results: data from clinical and biochemical blood tests, lipid profile; instrumental examination: performing electrocardiography and evaluating data from a sonographic examination of the abdominal organs; questionnaire using the Hospital Anxiety and Depression Scale (HADS, 1983) to assess the psychological status of the patient; questionnaire using the 36-Item Short Form Survey (SF-36, 1992).

Keywords: features of the psycho-emotional sphere, patients with metabolic syndrome, questionnaires using the Hospital Anxiety and Depression Scale (HADS, 1983), assessment of the patient’s psychological status; questionnaire using the 36-Item Short Form Survey (SF-36, 1992).

First page

612

Last page

615

For citation: Artykova M.A., Mamasoliev Sh.M. - FEATURES OF THE PSYCHOEMOTIONAL SPHERE IN PATIENTS WITH METABOLIC SYNDROME//New Day in Medicine 4(66)2024 612-615 https://newdayworldmedicine.com/en/article/3758

List of References

1. Бокарев И. Н. Метаболический синдром // И. Н. Бокарев // Журнал клиническая медицина. 2014;9(8):71.
2. Бородина С. В. Генетические предикторы развития ожирения [Текст]/ С. В. Бородина, К. М. Гаппарова, З. М. Зайнудинов, О. Н. Григорьян // Ожирение и метаболизм. 2016;13(2):7-13.
3. Василенко М. А. Роль продукции адипсина и лептина в формировании инсулинорезистентности у больных абдоминальным ожирением / М. А. Василенко, Е. В. Кириенкова, Д. А. Скуратовская [и др.] // Доклады Академии наук. 2017;475(3):336-341.
4. Верткин А. Л. Коморбидность: история, современное представление, профилактика и лечение. / А. Л. Верткин // Кардиоваскулярная терапия и профилактика. 2015;14(2):74-79.
5. Altin S. Metabolic syndrome does not impair the response to alfuzosin treatment in men with lower urinary tract symptoms: a double-blind, randomized, placebo-controlled study / S. Altin, T. Ozan, S. Ilhan et al. // Turk J Urol. 2015;41(3):125-131.
6. Di Bello, J. R. Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: a large cross-sectional, UK epidemiological study / J. R. Di Bello, C. Ioannou, J. Rees et al. // BJU Int. 2016;117(5):801-808.

   file

   download